We partner with the media to inform the public of the global human crisis.
Updates on the Department of Justice Action
Get updates and information on Indivior’s ongoing response to the recent action by the U.S. Department of Justice and learn about the company’s unwavering commitment to patients, doctors, and communities fighting opioid addiction.
See more >
May 14, 2020Q1 2020 Indivior Financial Results Press Release...
May 6, 2020Indivior receives approval for SUBUTEX® prolonged release solution for injection, 100mg and 300mg for substitution treatment of opioid dependence in Sweden...
April 27, 2020Directorate Change...
April 20, 2020Indivior to Announce Q1 2020 Results - May 14th...
April 16, 2020SUBLOCADE® Long-Term Safety Data Published in Journal of Clinical Psychopharmacology...
Global Media Contacts
EMEA, Australasia and China Financial Disclosure Reporting
Disclosure Of Payments, Donations & Joint Working
The Online Press Kit is designed to help media research our company for background information or follow-up stories. Please visit the links below to learn more.
About Indivior PLC – An overview of Indivior, including our worldwide locations and key products
Board of Directors – Biographies of Indivior’s Board
The Indivior PLC Pipeline – Information about the Indivior R&D efforts and progress of medicines in the pipeline